Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD (L452R+T478K) mutant (delta variant B.1.617.2 lineage
Cat No.: GMP-V-2019nCoV-Smu-023
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Package | Catalog No. | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
1mg | GMP-V-2019nCoV-Smu-023-1mg | 5990 | ||
10mg | GMP-V-2019nCoV-Smu-023-10mg | 38790 | ||
100mg | GMP-V-2019nCoV-Smu-023-100mg | 258000 | ||
≥100mg | GMP-V-2019nCoV-Smu-023-xmg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Accession Number | QHD43415.1 |
Expression platform | 2019-nCoV(SARS-CoV-2, SARS2-coronavirus) |
Isotypes | Mamamlian (human cell) |
Tag | C-His |
Products description | Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD L452R mutant (double mutant variant B.1.617 lineage, S:E484Q+L452R (India)) was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus. |
Bioactivity validation | ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays; |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay. |
predicted Molecular Mass | 26kDa |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD L452R mutant (double mutant variant B.1.617 lineage, S:E484Q+L452R (India))
The world is in midst of the COVID-19 pandemic. Recently A new "double mutant" variant of the coronavirus has been detected from samples collected in India. The two mutations (E484Q and L452R mutations) come together in the same virus, may be more infectious or less affected by vaccines.1
Mutations of Spike protein in SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India)
Two of the spike mutations are at key residues in the RBD (E484Q and L452R), two are in the N-terminal domain (T95I and E154K).
Spike Mutation in SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India) | Spike-S1 Subunit N Terminal |
T95I | |
E154K | Important residues mutation | ||
Spike-RBD | L452R | Important residues mutation | |
E484Q | Important residues mutation | ||
Spike-S1 Subunit | D614G | A popular mutation in different new SARS-CoV-2 lineage | |
Spike-S2 Subunit | P681R |
Figure. Amino acid changes in the spike region of the double mutant variant B.1.617 lineage, S:E484Q+L452R (India) genomes2
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
